XBRANE Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Xbrane Biopharma (STO: XBRANE)
›
Xbrane Biopharma (STO: XBRANE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 10.35 SEK on 20 November 2026, up 2.7% over 52 weeks. Its 52-week range is 5.421 SEK to 20.00 SEK: the price is 48.2% below the high and 90.9% above the low.
Its market capitalisation is 213.27M SEK.
Xbrane Biopharma reports return on equity of 22.7%, an operating margin of -28.4% and revenue up 441.3% year over year.
Its debt exceeds its cash by 26.52M SEK, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 17.00 SEK is 64.3% above the current price.